Oncology & Cancer

Closing the loop to target brain glioblastomas

"Closing the loop" has become one of the jargony cliches of the business world. But in the world of cancer immunotherapy, closing the loop could be an innovation that unlocks powerful therapies for hard-to-treat brain cancers ...

Oncology & Cancer

The protein behind immunotherapy resistance

Immunotherapy is a cutting-edge approach to treating cancer by turning the patient's own immune system against their tumor. Our increasing knowledge of the mechanisms by which the body regulates immune responses has been ...

Oncology & Cancer

New injectable gel offers promise for tough-to-treat brain tumors

Like the hardiest weed, glioblastoma almost always springs back—usually within months after a patient's initial brain tumor is surgically removed. That is why survival rates for this cancer are just 25 percent at one year ...

Oncology & Cancer

Immunotherapy to shrink treatment-resistant cancer tumors

Advancements in cancer research and treatment have resulted in great improvements in survival rates—today, there are almost 17 million people in the United States alone who have survived their diagnosis because of the physicians ...

page 4 from 40